Quadrant Capital Group’s Roivant Sciences ROIV Stock Holding History

Quadrant Capital Group’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.74M	Buy	49,246 +102	+0.2%	+$3.01K	0.05%	353
2026 Q1	$1.36M	Buy	49,144 +3,282	+7%	+$84.3K	0.04%	432
2025 Q4	$995K	Buy	45,862 +128	+0.3%	+$2.52K	0.03%	560
2025 Q3	$692K	Buy	45,734 +235	+0.5%	+$2.91K	0.02%	698
2025 Q2	$513K	Buy	45,499 +42,893	+1,646%	+$465K	0.02%	862
2025 Q1	$26.3K	Buy	2,606 +1,694	+186%	+$18.3K	﹤0.01%	1950
2024 Q4	$10.8K	Hold	912	–	–	﹤0.01%	2099
2024 Q3	$10.5K	Hold	912	–	–	﹤0.01%	2130
2024 Q2	$9.64K	Hold	912	–	–	﹤0.01%	2134
2024 Q1	$9.61K	Hold	912	–	–	﹤0.01%	2123
2023 Q4	$10.2K	Buy	912 +613	+205%	+$5.97K	﹤0.01%	2058
2023 Q3	$3.49K	Buy	299 +168	+128%	+$1.9K	﹤0.01%	2262
2023 Q2	$1.32K	Hold	131	–	–	﹤0.01%	2475
2023 Q1	$967	Hold	131	–	–	﹤0.01%	2543
2022 Q4	$1.05K	Buy	+131	New	+$729	﹤0.01%	2539

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Quadrant Capital Group's ROIV Position: Q2 2026 in Review

Quadrant Capital Group increased its Roivant Sciences (ROIV) stake by 0.21% in Q2 2026, buying an estimated $3.01K and bringing the position to 49,246 shares worth $1.74M. The position accounts for 0.05% of the portfolio, ranked #353.

Quadrant Capital Group first reported a position in ROIV in Q4 2022 and has held it in 15 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Quadrant Capital Group held 49,246 shares of Roivant Sciences worth $1.74M as of Q2 2026.
Quadrant Capital Group bought 102 Roivant Sciences shares in Q2 2026, an estimated $3.01K.
Roivant Sciences made up 0.05% of Quadrant Capital Group's portfolio in Q2 2026, its #353 holding.
Quadrant Capital Group first reported a position in Roivant Sciences in Q4 2022 and has held it in 15 quarters since.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.